Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.

Autor: Phillips MM; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Pavlyk I; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Allen M; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.; Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK., Cutts R; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Carpentier J; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Berry JS; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Nattress C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Feng S; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Hallden G; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Chelala C; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, CA, 92121, USA., Steele J; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK., Sheaff M; Department of Histopathology, Barts Health NHS Trust, Royal London Hospital, London, E1 1BB, UK., Balkwill F; Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK., Szlosarek PW; Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK. p.w.szlosarek@qmul.ac.uk.; Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. p.w.szlosarek@qmul.ac.uk.

Publikováno v: Pharmacological reports : PR [Pharmacol Rep] 2023 Jun; Vol. 75 (3), pp. 753.

Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent.

Autor: Serpi M; School of Chemistry, Cardiff University Main Building, Park Place, Cardiff CF10 3AT, Wales, U.K., Ferrari V; School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, U.K., McGuigan C; School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, U.K., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K., Pepper C; Brighton and Sussex Medical School, University of Sussex, Brighton BN1 9PX, U.K.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Dec 08; Vol. 65 (23), pp. 15789-15804. Date of Electronic Publication: 2022 Nov 23.

Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism

Autor: Bilanges, B, Alliouachene, S, Pearce, W, Morelli, D, Szabadkai, G, Chung, Y-L, Chicanne, G, Valet, C, Hill, JM, Voshol, PJ, Collinson, L, Peddie, C, Ali, K, Ghazaly, E, Rajeeve, V, Trichas, G, Srinivas, S, Chaussade, C, Salamon, RS, Backer, JM, Scudamore, CL, Whitehead, MA, Keaney, EP, Murphy, LO, Semple, RK, Payrastre, B, Tooze, SA, Vanhaesebroeck, B

Publikováno v: Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Nature Communications

Vps34 PI3K is thought to be the main producer of phosphatidylinositol-3-monophosphate, a lipid that controls intracellular vesicular trafficking. The organismal impact of systemic inhibition of Vps34 kinase activity is not completely understood. Here

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::de2a14aaadf0111aba8ffbf972e478d6
https://doaj.org/article/555f2b0adcb149a18a070a3da3035320

Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro .

Autor: Slusarczyk M; Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K., Serpi M; Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K., Ghazaly E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K., Kariuki BM; Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K., McGuigan C; Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K., Pepper C; Brighton and Sussex Medical School, University of Sussex, Medical Teaching Building, Brighton BN1 9PX, U.K.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jun 24; Vol. 64 (12), pp. 8179-8193. Date of Electronic Publication: 2021 Jun 04.